The Performance of Rapid Plasma Reagin (RPR) Titer in HIV-negative General Paresis After Neurosyphilis Therapy

BMC Infect Dis. 2018 Apr 2;18(1):144. doi: 10.1186/s12879-018-3062-4.

Abstract

Background: Repeated nontreponemal serologic test for syphilis titers is recommended to evaluate treatment response. However, it is unknown whether serum rapid plasma reagin (RPR) titer can serve as a surrogate for determining the efficacy of treatment in general paresis (GP) remains unknown.

Methods: We retrospectively reviewed data from 105 GP patients, who were divided into two groups (62 CSF RPR+ patients and 43 CSF RPR- patients) according to reactive RPR test status in CSF. Clinical assessment included the Mini-Mental State Examination (MMSE) scores, CSF examinations (WBC count, protein concentration and RPR titer), and serum tests (RPR titer and TPPA). Among the 105 GP patients, 13 CSF RPR+ patients and 6 CSF RPR- patients had a 12 months follow-up of CSF, serum measures and MMSE.

Results: The median serum RPR titer was significantly higher in CSF RPR+ patients than that in CSF RPR- GP patients, 1:8 [IQR 1:4-1:32] vs. 1:4 [IQR 1:4-1:8] (P < 0.001). The number of CSF RPR+ patients with serum RPR titer≥1:32 was significantly higher when compared with CSF RPR- patients (P = 0.001). For CSF RPR+ patients, the MMSE scores improved or remained constantly after penicillin treatment. For CSF RPR+ patients, the CSF RPR titer declined four-fold in 85% (11/13) of the patients, whereas the serum RPR titer declined four-fold in only 46% (6/13) of the patients, the odds ratio is 6.4 (95% confidence interval 1.0-41.2).

Conclusions: A four-fold decline in CSF RPR titer is a good predictor for treatment efficacy in CSF RPR+ GP patients within 12 months after the completion of therapy.

Keywords: General paresis; HIV-negative; Neurosyphilis; Rapid plasma regain.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Biomarkers / blood
  • Female
  • HIV Seronegativity*
  • Humans
  • Male
  • Middle Aged
  • Neurosyphilis / blood*
  • Neurosyphilis / diagnosis
  • Neurosyphilis / therapy*
  • Predictive Value of Tests
  • Prognosis
  • Reagins / analysis
  • Reagins / blood*
  • Retrospective Studies
  • Serologic Tests
  • Syphilis Serodiagnosis*
  • Treatment Outcome

Substances

  • Biomarkers
  • Reagins